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Abstract
Background: Central nervous system is a very rare site of Kaposi’s sarcoma in acquired immunodeficiency
syndrome. Kaposi’s sarcoma, a neoplasm of endothelial origin, occurs mainly in the skin, but can involve many
tissues, especially in patients with a poor immunity. Combination antiretroviral therapy, highly active against human
immunodeficiency virus type-1, has caused a dramatic reduction of cutaneous and visceral involvements. No report
of central nervous system localization of Kaposi’s sarcoma is described since the introduction of combination
antiretroviral therapy in the late 90’s.
Case presentation: A 42 year-old Caucasian man affected by human immunodeficiency virus type-1 infection
treated with combination antiretroviral therapy and showing relatively preserved immunity with low viral load
presented gingival squamous cell carcinoma and visceral (lungs and lymph nodes) Kaposi’s sarcoma. Chemotherapy
and radiotherapy were performed with improvement of both neoplasms. Afterwards, a magnetic resonance
imaging showed focal lesions of the brain. Despite new chemotherapy and radiotherapy the patient died. Histology
after autopsy revealed brain lesions due to Kaposi’s sarcoma with the detection of Human Herpesvirus 8 on tissue
samples.
Conclusions: This is the first report in the combination antiretroviral therapy era of a very rare complication of
Kaposi’s sarcoma, such as that of brain localization, in a patient with a relatively good control of human
immunodeficiency virus infection. Therefore, Kaposi’s sarcoma should be considered in differential diagnosis with
other intracranial mass lesions that can occur in human immunodeficiency virus infected-patients focusing the issue
of appropriate treatment for central nervous system involvement.
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Background
Since the first appearance, acquired immunodeficiency
syndrome (AIDS) and Kaposi’s sarcoma (KS), a multi-
centric angioproliferative spindle cell tumor of endothelial
origin, were associated [1]. KS can occur in many tissues,
mainly in the skin, but also in visceral sites involving
various organs like the gastrointestinal tract, the lungs, the
lymph nodes, and the bone. For mucocutaneous KS an
inspective, presumptive diagnosis is accepted [2]. DNA
sequences of a new γ-herpesvirus were shown to be invari-
ably present in KS lesions, but not in unaffected skin or in
several other diseased tissues; hence the new virus was
named KS-associated herpesvirus [3]. This virus belongs
to the herpesviridae family, and is also taxonomically clas-
sified as Human Herpesvirus 8 (HHV8). The causal asso-
ciation between HHV8 and KS has been subsequently
proven by unequivocal evidence, including the overlapping
global patterns of disease incidence and viral seropreva-
lence [4] and gave a support for the diagnosis. However,
for diagnosis of certain localizations, other than mucocu-
taneous forms like lymph nodes and bone, histological
examination remains necessary, because a differential diag-
nosis between KS and other diseases is required. Currently
KS continues to represent one of the most relevant cause
of AIDS-defining events, although less frequently since the
introduction of combination antiretroviral therapy (cART),
which caused a dramatic reduction of cutaneous manifest-
ation and visceral involvements [5]. Central nervous system
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(CNS) is a very rare site of KS, both in the human im-
munodeficiency virus type 1 (HIV-1) [6] and in the general
population setting [7]. Isolated histological cases of brain
KS in HIV-infected patients were reported at the beginning
of the AIDS era and before the introduction of cART.
Some were fully characterized cases, others were found in
CNS diseases studies or in retrospective autoptic series of
HIV-infected patients [8-13]. Up to now, no report of brain
localization is described in cART era.
We here describe the case of a HIV-1-infected patient
with KS involvement of the brain, focusing on histo-
pathological, virological and radiological features.
Case presentation
A 42 year-old Italian man diagnosed with HIV-1 infection
since 1993, was admitted at our hospital in April 2011
complaining about an acute pain at the right zygoma. At
medical examination he had a vegetated lesion of the
gingiva, arising from the superior maxilla, and an enlarge-
ment of right supraclavear lymph nodes. Examination of
the other organs was normal. CD4+ cell count was
243/mm3 and HIV-1 RNA in plasma was 68 copies/mL.
At clinical history, cutaneous and pulmonary KS had
been diagnosed in 1993 and at that time successfully
treated with interferon alfa and chemotherapy. CD4+
cell count nadir was 52/mm3 and hepatitis C virus coin-
fection was documented. In recent years, only occasional
bacterial pneumonia had occurred. cART was started in
1997 and changed to various regimens up to 2008, since
when the current cART based on co-formulated tenofovir-
emtricitabine, raltegravir, and darunavir/ritonavir had been
prescribed. This salvage therapy was chosen after HIV
genotypic resistance test that documented mutation asso-
ciated with multidrug resistance. CD4+ cell count had
stably risen above 200/mm3 since December 2008 and
HIV-1 RNA level was constantly below 500 copies/mL
since October 2009.
During hospitalization a total body computerized tom-
ography (CT) showed multiple nodular lesions in both
lungs, minimal right pneumothorax, pathological soft tis-
sue in the right maxillar sinus, and enlargement of supra-
clavear lymph nodes. CT scan of the brain was normal.
Biopsy specimen from gingival lesion revealed squamous
cell carcinoma, while tissue taken from supraclavear lymph
node showed histological features of KS. HHV8-DNA by
polymerase chain reaction (PCR) was negative on blood.
Four cycles of chemotherapy using liposomial doxorubicin
(20 mg/m2) were performed, and after only two cycles an
improvement of CT findings was documented. Then, ten
sessions of radiotherapy on maxillofacial site for carcinoma
were performed (total dose 30 Gy).
In October 2011, the patient showed bilateral spontan-
eous pneumothorax and was treated with chest drainage.
After 25 days, he presented generalized seizures. A
magnetic resonance imaging (MRI) of the brain showed
three focal brain lesions, two that involved the right
frontal lobe (20 and 14 mm) and one the right cerebellum
hemisphere (16 mm). On FLAIR T2-weighted images
the lesions of the right frontal lobe were hyperintense,
with hypointense halo and surrounding edema. Diffusion-
weighted imaging (DWI) showed restricted diffusion and
low apparent diffusion coefficients (ADCs) in the lesions
(range avg 0,458-0,566x10(−3)mm(2)/s). A new total body
CT displayed a worsening of the previously described
pulmonary lesions and the development of new intestinal
lesions. A multi-disciplinary consultation excluded the
possibility to carry out a cerebral biopsy, because of the le-
sion high risk of bleeding. CD4+ cell count was 142/mm3
and HIV-1 RNA in plasma was 225 copies/mL. HHV8-
DNA by PCR on blood was repeatedly negative and IgG
anti-Toxoplasma gondii antibodies were absent. Never-
theless, empiric anti-Toxoplasma treatment with pyrime-
tamine plus sulfadiazine, combined with steroids and
phenobarbital, was prescribed. Brain MRI after 26 days of
treatment showed worsening of the CNS disorder, with
the appearance of a new lesion in the left frontal lobe dis-
playing the same radiological characteristics. There was no
change in signal intensity or size of the lesions already de-
scribed in the previous examination. The lesions appeared
as inhomogeneous masses, hyperintense on T1- and on
T2-weighted images (Figure 1A, B, C), with halo hypoin-
tense sign and surrounding edema, minimal mass effect
and faintly ring enhancement. DWI of the lesions showed
restricted diffusion (Figure 1D) and lower ADC (avg
0,285×10(−3)mm(2)/s). Thallium-201 single-photon emis-
sion computed tomography (201Tl SPECT) of the brain
did not show an increased uptake in the brain. 18 F-2-
Fluoro-2-deoxy-d-glucose (FDG) positron emission tom-
ography (PET) of the neck, thorax and abdomen showed
hyperperfused tissue in the right cervical lymph nodes,
skeleton, right adrenal gland, lungs, right maxillar sinus,
duodenum. On the 1st of December a cycle of paclitaxel
(100 mg/m2) was administered, and then ten sessions of
whole brain radiotherapy were performed (total dose
30 Gy). At the end of December a massive right spontan-
eous pneumothorax occurred and pleural drainage was
necessary again. The patient died on January 6th, 2012.
A full autopsy, including neuropathological examin-
ation, was performed. Tissue samples were taken from
all organs. KS was found in the lungs, the ampulla of
Vater, the pancreas, the duodenum, the adrenal gland
and the cerebrum. Macroscopic examination revealed
hemorrhagic nodules, variegated in appearance, with
cystic degeneration in the organs involved. Multiple
bilateral areas of consolidation with cavitation and
necrotizing nodular lesions were present in the lungs.
Cavities were extended to the pleura. Coronal section of
the brain showed multiple hemorrhagic nodules with
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swelling of the cerebrum without displacement of
midline structures. Lesions were localized in the frontal
lobes at the gray/white matter interface, near the falx
and in the cerebellum. Microscopic appearance of the
tumor nodules was composed of monomorphic spindle
cells arranged in ill defined fascicles (Figure 2A) and
separated by slit like vessels containing erythrocytes.
Brain parenchyma of both cerebellar and cerebral
hemispheres was invaded by the tumor cells directly or
through the perivascular space (Figure 2B). Neoplastic
nodules showed hemorrhagic necrosis with pigmented
macrophages (Figure 2C). Immunohistochemical stain-
ing of the tumour cells revealed strong expression of
CD34 (Figure 2D). Real time PCR assays [14] revealed
HHV8 DNA sequences in the tissue samples from the
duodenum, the lungs and the brain. Quantitative evalu-
ation of HHV8 DNA in the lungs, the Vater’s papilla
and the brain showed: 15872 copies/106 cells, 7789
copies/106 cells and 2316 copies/106 cells respectively.
Conclusions
This case report describes an HIV-1-infected patient
presenting brain localization of KS, despite previously
administered chemoterapy and cART treatment. Disease
localization was documented by accurate histological,
virological and radiological examination with MRI and
DWI. At first evaluation of the patient, absence of cutane-
ous neoplastic lesions, immunological status with CD4+
cell count stably above 200/mm3, HIV-1 RNA of 68
copies/mL, negative HHV8 PCR in the peripheral blood,
and diagnosis of concurrent gingival carcinoma made the
diagnosis of KS unlikely.
In the pre-cART era, HIV-1-infected patients with KS
typically had a low CD4 cell count and a high HIV viral
load. Since the introduction of cART, the incidence of KS
has decreased [5] and survival improved [15,16]. Further,
it is well documented that cART, especially HIV protease
inhibitors, can improve KS lesions with or without use of
liposomal anthracycline [15,17]. However, unusual cases
Figure 1 Magnetic Resonance Images (MRI) of the brain at control after 26 days of anti-Toxoplasma treatment. A. On Axial FLAIR
T2-weighted images the lesions are hyperintense, with hypointense halo and surrounding edema. B. Diffusion-weighted imaging of the lesions
showed restricted diffusion. C. On unenhanced Axial T1-weighted images the lesions signal is heterogeneous. D. On enhanced Axial T1-weighted
images faint lesions enhancement are depicted.
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of cutaneous HIV-associated KS occurring even during
stable immunologic rescue and HIV-RNA suppression in
plasma are reported [18,19].
Our patient was cART-experienced, with genotypic
multi-drug resistance in HIV. Despite the high-level resist-
ance, re-optimized cART allowed to obtain stable low-
level viremia in plasma close to 50 copies/mL cut-off.
Biopsy of the lymph node revealed histologic KS and
allowed starting chemotherapy with improvement of vis-
ceral lesions. At the onset of neurological symptoms, brain
mass lesions at MRI were detected. Radiologic features of
intracranial KS have only rarely been described; intracra-
nial masses of the patient had a vascular component, and
appeared as a inhomogeneous mass with hyperintense sig-
nal on T1- and on T2-weighted images, with surrounding
edema, minimal mass effect and with faintly ring enhance-
ment. The hyperintensity on T1-weighted images probably
was due to abnormally increased blood vessels with slow
intra-lesional flow. The low ADC value of KS lesions
might be due to its histological architecture made of high
tumor cellularity and relatively large vascular spaces. Al-
though no studies have elucidated the direct relationship
between blood flow velocity and vascular spaces size we
hypothesise that blood velocity in KS lesions is low be-
cause of the large vascular spaces, and that this may deter-
mine the increased signal strengths and lower ADCs on
DWI. FDG-PET of the body only showed the suspicion of
neoplastic disease in various tissues, but FDG-PET of the
brain unfortunately was not performed. Only autopsy
specimens allowed obtaining the diagnosis of KS, that was
confirmed by the detection of HHV8-DNA in the brain
tissues. In HIV-infected patients, differential diagnosis of
mass lesions is required. Mass algorithms in the pre-cART
era were well defined, but in the cART era, when the epi-
demiology of opportunistic infections changed, are lack-
ing. Brain biopsy, if feasible, is no longer mandatory for
the diagnosis of mass lesions in HIV-patients [20], how-
ever histological examination in some cases is still the only
way to obtain a definitive diagnosis.
Only few histologically proven cases of KS metastatic to
the brain in HIV-1 patients have been described: up to
now Gorin et al. reported two cases at the beginning of the
AIDS era [8], and Buttner et al. described in 1997 a patient
who had never taken cART [9]. Two more cases were pub-
lished by Levy et al. [10] and one was observed by Post
et al. in CNS diseases studies performed in the 80’s [11]. In
a morphological analysis of brains from 100 AIDS patients
observed in the course of 1987–1995 years, Mossakowski
et al. found one case of cerebral KS [12], so did Jellinger
et al. in a retrospective study on 450 consecutive autoptical
AIDS cases between 1984 and 1999, only in the cohort
of 1984–1992 [13]. Most of these cases were observed in
advanced patients with other concomitant AIDS-related
events and none occurred during antiretroviral treatment.
Moreover, in our patient cART was mainly effective, with
low plasma viral copies and partial immune recovery.
The cause of brain involvement in this patient despite an
initial improvement of visceral lesions with the appropriate
Figure 2 Histological findings in blood-borne brain lesion. A. The multiple hemorrhagic nodules showed whorls of spindle-shaped cells
and neovascularization with small-vessel proliferation characteristic of Kaposi’s sarcoma (hematoxylin-eosin stain; original magnification, ×400).
B. Tumour cells invaded brain parenchyma through perivascular space (hematoxylin-eosin stain; original magnification, ×200). C. Neoplastic
nodules showed hemorrhagic necrosis with pigmented macrophages (hematoxylin-eosin stain; original magnification, ×200). D. The neoplastic
cells show strong cytoplasmic staining for CD34 (immunoperoxidase on a paraffin embedded section, original magnification, ×400).
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treatment [21], is difficult to explain. Furthermore, it is
well documented that positive HHV8 DNA on peripheral
blood or a CD4 level below 200/mm3 are risk factors of
poor evolution of KS [22], but the patient had a stable im-
munity and a persistent negative blood HHV8 DNA. Des-
pite incomplete suppression of HIV-1 replication, cART
was effective to prevent the development of opportunistic
infections in all the clinical history of the patient. We
know that HIV-1 plays a role on the KS diffusion through
the production and the release of the HIV-1 Tat protein, a
KS progression factor, and that cART has a documented
direct anti-angiogenetic effect [23,24]. In this case, inde-
pendently of the CD4 cell count, the incomplete suppres-
sion of HIV-1 could have enhanced the diffusion of KS,
producing an increased release of the HIV-1 Tat protein.
This case describes a rare complication of KS, never
reported in the cART era, and raises a question about the
diagnosis and the treatment suggesting that KS should be
considered for the differential diagnosis with other intra-
cranial mass lesions that can occur in HIV patients and
focusing on the problem of appropriate treatment for
CNS involvement.
The case described was approved by an internal revision
group at the Direction of Clinical Department.
Consent
Written informed consent was obtained from the wife of
the patient for publication of this case report and any
accompanying images. A copy of the consent form is
available for review by the Editor of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FB: study concept, acquisition, analysis and interpretation of data, drafting
and critical revision of the manuscript. AB, VS, CA, FDN, MRC: acquisition,
analysis and interpretation of data, drafting of the manuscript. MLG, AA:
study concept and design, drafting and critical revision of the manuscript.
LA, SG: acquisition of data, critical revision of the manuscript. All the authors
approved the final version of the manuscript.
Acknowledgments
We thank S. Paradiso and V. Scopece for their expert technical assistance;
and Dr. R. Mancini and M. D’Adduogo for help in bibliographic research.
Author details
1Clinical Department, National Institute for Infectious Diseases “L. Spallanzani”
IRCCS, Via Portuense 292, 00149 Rome, Italy. 2Department of Pathology,
National Institute for Infectious Diseases “L. Spallanzani” IRCCS, Via Portuense
292, 00149 Rome, Italy. 3Diagnostic Department, National Institute for
Infectious Diseases “L. Spallanzani” IRCCS, Via Portuense 292, 00149 Rome,
Italy. 4Laboratory of Virology, National Institute for Infectious Diseases “L.
Spallanzani” IRCCS, Via Portuense 292, 00149 Rome, Italy.
Received: 3 September 2013 Accepted: 16 December 2013
Published: 21 December 2013
References
1. Friedman-Kien AE, Laubenstein LJ, Rubinstein P, Buimovici-Klein E, Marmor
M, Stahl R, Spigland I, Kim KS, Zolla-Pazner S: Disseminated Kaposi’s
sarcoma in homosexual men. Ann Intern Med 1982, 96:693–700.
2. Centers for Disease Control and Prevention (CDC): 1993 revised
classification system for HIV infection and expanded surveillance case
definition for AIDS among adolescents and adults. MMWR Recomm Rep
1992, 41:1–19.
3. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore
PS: Identification of herpesvirus-like DNA sequences in AIDS-associated
Kaposi’s sarcoma. Science 1994, 266:1865–1869.
4. Mesri EA, Cesarman E, Boshoff C: Kaposi’s sarcoma and its associated
herpesvirus. Nat Rev Cancer 2010, 10:707–719.
5. Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova
N, Antunes F, Stellbrink HJ, Phillips AN, Lundgren JD: The changing pattern
of Kaposi sarcoma in patients with HIV, 1994–2003: the EuroSIDA Study.
Cancer 2004, 100:2644–2654.
6. Pantanowitz L, Dezube BJ: Kaposi sarcoma in unusual locations.
BMC Cancer 2008, 8:190.
7. Bahat E, Akman S, Karpuzoglu G, Aktan S, Ucar T, Arslan AG, Nenonen N,
Gur Guven A, Karpuzoglu T: Visceral Kaposi’s sarcoma with intracranial
metastasis: A rare complication of renal transplantation. Pediatr
Transplantation 2002, 6:505–508.
8. Gorin FA, Bale JF Jr, Halks-Miller M, Schwartz MA: Kaposi’s sarcoma
metastatic to the CNS. Arch Neurol 1985, 42:162–165.
9. Buttner A, Marquart KH, Mehraein P, Weis S: Kaposi’s sarcoma in the
cerebellum of patient with AIDS. Clin Neuropathol 1997, 16:185–189.
10. Levy RM, Pons VG, Rosenblum ML: Central nervous system mass lesions in
the acquired immunodeficiency syndrome (AIDS). J Neurosurg 1984,
61:9–16.
11. Post MJ, Sheldon JJ, Hensley GT, Soila K, Tobias JA, Chan JC, Quencer RM,
Moskowitz LB: Central nervous system disease in acquired
immunodeficiency syndrome: prospective correlation using CT, MR
imaging, and pathologic studies. Radiology 1986, 158:141–148.
12. Mossakowski MJ, Zelman IB: Neuropathological syndromes in the course
of full blown acquired immune deficiency syndrome (AIDS) in adults in
Poland (1987–1995). Folia Neuropathol 1997, 35:133–143.
13. Jellinger KA, Setinek U, Drlicek M, Böhm G, Steurer A, Lintner F:
Neuropathology and general autopsy findings in AIDS during the last
15 years. Acta Neuropathol 2000, 100:213–220.
14. Lallemand F, Desire N, Rozenbaum W, Nicolas JC, Marechal V: Quantitative
analysis of human herpes 8 viral load using a real-time PCR assay.
J Clin Microbiol 2000, 38:1404–1408.
15. Holkova B, Takeshita K, Cheng DM, Volm M, Wasserheit C, Demopoulos R,
Chanan-Khan A: Effect of highly active antiretroviral therapy on survival
in patients with AIDS-associated pulmonary Kaposi’s sarcoma treated
with chemotherapy. J Clin Oncol 2001, 19:3848–3851.
16. Martinez V, Caumes E, Gambotti L, Ittah H, Morini JP, Deleuze J, Gorin I,
Katlama C, Bricaire F, Dupin N: Remission from Kaposi’s sarcoma on
HAART is associated with suppression of HIV replication and is
independent of protease inhibitor therapy. Br J Cancer 2006,
94:1000–1006.
17. Nasti G, Martellotta F, Berretta M, Mena M, Fasan M, Di Perri G, Talamini R,
Pagano G, Montroni M, Cinelli R, Vaccher E, D’Arminio Monforte A, Tirelli U:
Impact of highly active antiretroviral therapy on the presenting features
and outcome of patients with Acquired Immunodeficiency Syndrome–
Related Kaposi sarcoma. Cancer 2003, 98:2440–2446.
18. Maurer T, Ponte M, Leslie K: HIV-associated Kaposi’s sarcoma with a high
CD4 count and a low viral load. N Engl J Med 2007, 357:1352–1353.
19. Krown SE, Lee JY, Dittmer DP: More on HIV-associated Kaposi’s sarcoma.
N Engl J Med 2008, 358:535–536.
20. Antinori A, Ammassari A, Luzzati R, Castagna A, Maserati R, Rizzardini G,
Ridolfo A, Fasan M, Vaccher E, Landonio G, Scerrati M, Rocca A, Butti G,
Nicolato A, Lazzarin A, Tirelli U: Role of brain biopsy in the management
of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo
AIDS & Tumori. Neurology 2000, 54:993–997.
21. Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo
N, Powles T, Stebbing J, Wales N, Webb A, AIDS Malignancy Subcommittee:
British HIV Association guidelines for HIV-associated malignancies 2008.
HIV Med 2008, 9:336–388.
22. El Amari EB, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G,
Steffen I, Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH,
Bernasconi E, Hirschel B, Swiss HIV Cohort Study: Predicting the evolution
of Kaposi sarcoma, in the highly active antiretroviral therapy era.
AIDS 2008, 22:1019–1028.
Baldini et al. BMC Infectious Diseases 2013, 13:600 Page 5 of 6
http://www.biomedcentral.com/1471-2334/13/600
23. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C,
Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G,
Bussolino F, Monini P, Ensoli B: HIV protease inhibitors are potent
anti-angiogenic molecules and promote regression of Kaposi sarcoma.
Nat Med 2002, 8:225–232.
24. Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz MS Jr, Weichold FF:
Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of
Kaposi sarcoma. Blood 2002, 99:3771–3779.
doi:10.1186/1471-2334-13-600
Cite this article as: Baldini et al.: Brain localization of Kaposi’s sarcoma in
a patient treated by combination antiretroviral therapy. BMC Infectious
Diseases 2013 13:600.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Baldini et al. BMC Infectious Diseases 2013, 13:600 Page 6 of 6
http://www.biomedcentral.com/1471-2334/13/600
